nuklearmedizin - nuclearmedicine
130620
DE
EN
Home
Products
Journals
Books
Book Series
Service
Library Service
Help
Contact
Portal
Nuklearmedizin - NuclearMedicine
Full-text search
Full-text search
Author Search
Title Search
DOI Search
Metadata Search
Journal
About this journal
Editorial Board
Impact Factor
Imprint
Job Board
Media
Authors
Instructions for authors
Subscription
Subscription Information
Institutional Licensing
Affiliated Societies
Deutsche Gesellschaft für Nuklearmedizin (DGN)
Österreichische Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (OGNMB)
Schweizerische Gesellschaft für Nuklearmedizin (SGNM/SSNM)
PharmaMarket
PharmaMarket
Not Logged In
Login
Username or e-mail address:
Password:
Forgot Access Data?
Register Now
OpenAthens/Shibboleth Login
Shopping Cart
Year (Archive)
2024
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
1982
1981
1980
1979
1978
1977
1976
1975
1974
1973
1972
1971
1970
1969
1968
1967
1965
1964
1963
1962
1961
Issues
Current Issue
Free Sample Issue (01/2024)
Abstracts (HTML)
List of Authors
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Å
Cachovan, M
The CCK-2 receptor agonist Lu-177-PP-F11N for PRRT of medullary thyroid cancer – Recent results of the phase 1 “LUMED” Study
Data-Driven Respiratory SPECT-Gating for Determination of Liver-Lung-Shunt Fraction
Cala, L
Nephrotoxicity after PSMA-RLT using Lu-177-PSMA I&T
Ceccon, G
Diagnosis of pseudoprogression following lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients using FET PET
Celik, E
Diagnosis of pseudoprogression following lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients using FET PET
Centurioni, G
Texture analysis of liver NET liver metastases on Ga-68 DOTATATE PET candidate to PRRT: non-invasive histological and prognostic stratification
Chantadisai, M
Prä-therapeutische Dosimetrie von Lu-177-rhPSMA7.3 und Lu-177-PSMA-I&T bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC)
Chiti, A
18
F-FDG PET radiomics predicts pathological data and survival of intrahepatic cholangiocarcinoma
Choi, H
Spatial distribution pattern of tau depositions in Alzheimer’s disease using data-driven approach of flortaucipir PET
Christ, ER
The CCK-2 receptor agonist Lu-177-PP-F11N for PRRT of medullary thyroid cancer – Recent results of the phase 1 “LUMED” Study
Christl, A
In ovo imaging using ostrich eggs – physiological embryonal development on serial CT scans
Christoph, C
Reconstruct gamma-ray interaction position for the development of an on-chip PET system using deep learning
Classen, J
Multicenter F-18-PI-2620 PET for in vivo Braak staging of tau pathology in Alzheimer’s disease
Potential of F-18-PI-2620 Tau PET to Improve the Imaging-Based Diagnosis of Progressive Supranuclear Palsy (PSP)
F18-PI-2620 und Quantitative Susceptibility Mapping (QSM) am PET/MRT bei Patienten mit progressiver supranukleärer Blickparese (PSP)
Clauß, O
Synthese von neuartigen selektiven Histondeacetylase (HDAC)-Inhibitoren zur Entwicklung geeigneter
18
F-markierter Radiotracer für die bildgebende Darstellung epigenetischer Prozesse in Tumoren
Conen, P
Molecular imaging for the detection of kidney fibrosis in patients with varying chronic kidney disease (CKD) stages
Conti, M
A comparison of detectability and image quality in Iodine-124 PET across different PET system generations to optimize the protocol for recurrent thyroid cancer patients
Conti, P
Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)
Cordes, M
68
Ga-FAPI-04 PET/CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-related interstitial lung disease
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
Costa, G
18
F-FDG PET radiomics predicts pathological data and survival of intrahepatic cholangiocarcinoma
Costa, PF
Ga-68-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma (HCC)
Craig, A
Präklinische Evaluation von 3-L- und 3-D-F-18-Fluorophenylalaninen (3-L- und 3-D-F-18-FPhe)
Cyran, CC
Dosimetry and optimal time frame of [
18
F]SiTATE PET/CT in Patients with Neuroendocrine Carcinoma